
Autonomize
Founded Year
2022Stage
Incubator/Accelerator - II | AliveTotal Raised
$32MMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+151 points in the past 30 days
About Autonomize
Autonomize provides healthcare AI solutions within the healthcare and life sciences sectors. Its offerings include tools that organize, contextualize, and summarize unstructured data to support decision-making and enhance patient outcomes. The company's technologies aim to improve clinical workflows and reduce the burden on healthcare professionals. It was founded in 2022 and is based in Austin, Texas.
Loading...
Autonomize's Product Videos
Loading...
Research containing Autonomize
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Autonomize in 1 CB Insights research brief, most recently on Oct 20, 2025.

Oct 20, 2025 report
Digital Health 50: The most promising digital health startups of 2025Expert Collections containing Autonomize
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Autonomize is included in 5 Expert Collections, including Digital Health.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Generative AI
2,951 items
Companies working on generative AI applications and infrastructure.
Digital Health 50
100 items
Artificial Intelligence (AI)
20,894 items
AI agents & copilots
1,772 items
Companies developing AI agents, assistants/copilots, and agentic infrastructure. Includes pure-play emerging agent startups as well as companies building agent offerings with varying levels of autonomy.
Latest Autonomize News
Nov 6, 2025
Autonomize AI Joins Microsoft Pegasus Program to Boost Healthcare AI November 6, 2025 Collaboration empowers healthcare enterprises to scale AI innovation on Microsoft Azure, with healthcare-native Autonomize AI Agents to reduce administrative burden and improve care experience. Autonomize AI, a healthcare AI company pioneering enterprise-grade Agentic AI solutions, today announced its acceptance into the Microsoft for Startups Pegasus Program. The invite-only program accelerates venture-backed B2B startups through technical enablement and access to Microsoft’s global enterprise customer network. Participation in the Pegasus Program follows Autonomize AI’s recent $28 million Series A funding round and ongoing expansion of its leadership team, underscoring the company’s rapid momentum in transforming healthcare and life sciences organizations discover insights, improve decision-making, and deliver value through its healthcare-native AI platform and marketplace of healthcare-native AI Agents. As part of Project Pegasus, Autonomize AI will: Expand access by publishing its solutions directly on Microsoft Marketplace, making them easy to discover and deploy. Accelerate adoption through collaboration with Microsoft’s enterprise account teams to bring solutions to customers faster. Drive customer outcomes through coordinated go-to-market efforts, including opportunity generation and shared customer engagements. “Acceptance into the Microsoft for Startups Pegasus Program marks an important milestone for Autonomize AI as we scale to meet rising demand for AI that blends automation of manual tasks with augmenting human expertise,” said Ganesh Padmanabhan, Co-Founder & CEO of Autonomize AI. “With Microsoft’s technical and go-to-market collaboration, we are positioned to bring our accountable AI Agents to more healthcare enterprises—reducing administrative burden, empowering clinical teams, and accelerating care decisions in an industry that urgently needs both efficiency and trust.” Autonomize AI will host an upcoming webinar, ‘Building an Agentic Healthcare Enterprise with Autonomize AI on Microsoft Azure,’ spotlighting how the company helps health enterprises reduce administrative bottlenecks in complex operational workflows—blending automation with human expertise to deliver faster decisions, lower costs, and better patient experiences. Business Wire Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX Network. Business Wire has 18 newsrooms worldwide to meet the needs of communications professionals and news media. previous post
Autonomize Frequently Asked Questions (FAQ)
When was Autonomize founded?
Autonomize was founded in 2022.
Where is Autonomize's headquarters?
Autonomize's headquarters is located at 9390 Research Boulevard, Austin.
What is Autonomize's latest funding round?
Autonomize's latest funding round is Incubator/Accelerator - II.
How much did Autonomize raise?
Autonomize raised a total of $32M.
Who are the investors of Autonomize?
Investors of Autonomize include Microsoft for Startups Pegasus Program, ATX Venture Partners, Capital Factory, Asset Management Ventures, The Cigna Group Ventures and 9 more.
Who are Autonomize's competitors?
Competitors of Autonomize include Layer Health and 6 more.
Loading...
Compare Autonomize to Competitors

John Snow Labs is a healthcare artificial intelligence (AI) company focusing on AI and natural language processing (NLP) solutions for the healthcare and life sciences sectors. The company provides products including language models for clinical text summarization and question answering, NLP libraries for information extraction and de-identification, and tools for training and deploying AI models. John Snow Labs serves healthcare systems, pharmaceutical companies, and other entities in the healthcare industry. It was founded in 2015 and is based in Lewes, Delaware.

Dyania Health specializes in healthcare artificial intelligence (AI) and focuses on automating the manual review of patient medical histories. Its main offering, Synapsis AI, is a proprietary system that reads electronic medical records (EMRs) in a fraction of a second, enabling faster and more accurate clinical decision-making and patient care. It serves healthcare systems, physicians, and pharmaceutical sponsors by providing tools that support clinical trials and patient treatment processes. It was founded in 2019 and is based in Jersey City, New Jersey.

Massive Bio operates as an artificial intelligence (AI) driven platform specializing in personalized oncology solutions within the healthcare sector. The company offers services connecting cancer patients and oncologists to clinical trials for new, alternative, and targeted treatments, as well as providing personalized treatment recommendations through a virtual tumor board. It primarily serves the healthcare industry, particularly oncology care providers and cancer patients seeking treatment options. It was founded in 2014 and is based in Istanbul, Turkey.
Medaptive Health offers an open source solution for developing and operating consumer-facing health applications. Clients use the platform to develop and push content to participants, collect real world evidence, and analyze the resulting data. Because of our content-driven approach, clients can deploy a solution at a fraction of the time and cost of traditional approaches. The platform supports all devices (Android, iOS, web), as well as sensors and wearables.

ConcertAI specialises in generative and agentic artificial intelligence (AI) solutions within the life sciences and healthcare sectors. The company offers a suite of products that utilise real-world data and AI to support clinical research, facilitate clinical trials, and provide insights for oncology care. ConcertAI's services are directed towards life sciences and healthcare organisations looking to advance translational medicine. ConcertAI was formerly known as Concerto HealthAI. It was founded in 2017 and is based in Cambridge, Massachusetts.

COTA focuses on healthcare, specifically in the domain of cancer care. The company's main services involve the use of proprietary technology, advanced analytics, and deep expertise to organize complex data, providing a comprehensive picture of cancer to advance care and research. COTA primarily serves the healthcare industry, with a specific focus on oncology. It was founded in 2011 and is based in New York, New York.
Loading...